アドリアシン注引用文献一覧表...Patel SR, et al. Am. J. Clin. Oncol. 21(3),317-321,...

アドリアシン注

引用文献一覧表

協和醗酵工業株式会社

乳癌 AC 療法資料

番号表題著者

掲載雑誌

その他

①無作為化比較試験等の公表論文

1

Two months of Doxorubicin-Cyclophosphamide with

and without interval reinduction therapy

compared with 6 months of Cyclophosphamide,

Methotrexate, and Fluorouracil in positive-node

breast cancer patients with

Tamoxifen-nonresponsive tumors:Results from the

National Surgical Adjuvant Breast and Bowel

Project B-15

Fisher B, et al.J.Clin.Oncol.

8(9),1483-1496,1990

2

Tamoxifen and chemotherapy for axillary

node-negative, estrogen receptor-negative

breast cancer: Findings from National Surgical

Adjuvant Breast and Bowel Project B-23

Fisher B, et al.J. Clin. Oncol.

19（4）,931-942,2001

②教科書

3 Diseases of the breast, 2nd ed． Harris JR, et al.

Lippincott Williams

& Wilkins

599-632, 2000

4 Cancer,Principles & practice of oncology, 6th

edition．

De Vita VT, et

al.

Lippincott Williams

& Wilkins,

1692-1697, 2001

③peer－review journal に掲載された総説、メタ・アナリシス

5 Polychemotherapy for early breast cancer: an

overview of the randomised trials

Early Breast

Cancer

Trialists'

Collaborative

Group

Lancet

352,930-942,1998

6 Drug therapy：Treatment of breast cancer Hortobagyi GN.

New Engl. J. Med.

339(14),974-984,19

98

7

Drug therapy：

Side effects of adjuvant treatment of breast

cancer

Shapiro CL, et

al.

New Engl. J. Med.

344(26),1997-2008,

2001

④学会又は組織・機構の診療ガイドライン

8 科学的根拠に基づく乳癌診療ガイドライン作成に

関する研究

主任研究者高

嶋成光（乳癌学

会乳癌診療ガイ

ドライン原案）

平成１４年度厚生労

働化学研究費補助金

医療技術評価総合研

究事業研究報告書

142-143

9

Meeting highlights:updated international expert

consensus on the primary therapy of early breast

cancer

Goldhirsch A, et

al.

J. Clin. Oncol.

21(17):3357-3365

,2003

10

National Cancer Institute. Breast Cancer(PDQ)

Treatment;

－

http://www.nci.nih

.gov/cancertopics/

pdq/treatment/brea

st/healthprofessio

nal/allpages/print

11

National Comprehensive Cancer Network ：

Clinical Practice Guidelines in Oncology.

Breast Cancer. Ver1.2004.

-

http://www.nccn.or

g/physician_gls/f_

guidelines.html

１

http://www.nci.nih.gov/cancertopics/pdq/treatment/breast/healthprofessional/allpages/http://www.nci.nih.gov/cancertopics/pdq/treatment/breast/healthprofessional/allpages/http://www.nci.nih.gov/cancertopics/pdq/treatment/breast/healthprofessional/allpages/http://www.nci.nih.gov/cancertopics/pdq/treatment/breast/healthprofessional/allpages/http://www.nci.nih.gov/cancertopics/pdq/treatment/breast/healthprofessional/allpages/http://www.nccn.org/physician_gls/f_guidelines.htmlhttp://www.nccn.org/physician_gls/f_guidelines.htmlhttp://www.nccn.org/physician_gls/f_guidelines.html

骨・軟部腫瘍

資料番号

表題著者掲載雑誌その他


1 Randomized comparison of three adriamycin

regimens for metastatic soft tissue sarcomas. Borden EC, et al.

J. Clin. Oncol.

5(6),840-850,1987

2

Randomized comparison of Doxorubicin alone

versus Ifosfamide plus Doxorubicin or Mitomycin,

Doxorubicin, and Cisplatin against advanced soft

tissue sarcomas.

Edmonson JH, et

al.

J. Clin. Oncol.

11(7),1269-1275,1993

3

Doxorubicin versus CYVADIC versus Doxorubicin

plus Ifosfamide in first-line treatment of

advanced soft tissue sarcomas: A randomized study

of the European Organization for Research and

Treatment of Cancer Soft Tissue and Bone Sarcoma

Group.

Santoro A, et al. J. Clin. Oncol.

13(7),1537-1545,1995

4

An intergroup phase III randomized study of

Doxorubicin and Dacarbazine with or without

Ifosfamide and mesna in advanced soft tissue and

bone sarcomas.

Antman K, et al.J. Clin. Oncol.

11(7),1276-1285, 1993

5

Is high - dose chemotherapy of interest in

advanced soft tissue sarcoma (ASTS)?: An EORTC

randomized phase III trial.

Tursz T, et al.

Proceeding of the

American Society of

Clinical Oncology 15,

337, 1996(abstract)

6

High - dose Ifosfamide plus Adriamycin in the

treatment of adult advanced soft tissue sarcomas:

Is it feasible?

De Pas T, et al.Ann. Oncol.

9, 917-919,1998

7

Results of two consecutive trials of dose -

intensive chemotherapy with Doxorubicin and

Ifosfamide in patients with sarcomas.

Patel SR, et al.Am. J. Clin. Oncol.

21(3),317-321, 1998

8

Adjuvant chemotherapy for adult soft tissue

sarcomas of the extremities and girdles: Results

of the Italian randomized cooperative trial.

Frustaci S, et al.J. Clin. Oncol.

19(5), 1238-1247, 2001

9 Non rhabdo malignant mesenchymal tumors in

children. Sommelet-Olive D.

Med.Pediatr.Oncol.

25,273, 1995

(abstracts)

10

Randomised trial of two regimens of chemotherapy

in operable osteosarcoma: a study of the European

Osteosarcoma Intergroup.

Souhami RL et al. Lancet

350, 911-917,1997

11

Neoadjuvant chemotherapy for osseous malignant

fibrous histiocytoma of the extremity: Results in

18 cases and comparison with 112 contemporary

Osteosarcoma patients treated with the same

chemotherapy regimen.

Bacci G, et al. J. Chemother.

9(4),293-299, 1997

12

Neoadjuvant chemotherapy with Doxorubicin and

Cisplatin in malignant fibrous histiocytoma of

bone: A european osteosarcoma intergroup study.

Bramwell VHC, et

al.

J. Clin. Oncol.

17(10), 3260-3269,

1999

２

資料番号


②教科書

13 Oxford textbook of oncology 4 th ed. ― P2411-2516

14 Treatment of Cancer 4th ed． ― P866


15

Adjuvant chemotherapy for localised resectable

soft-tissue sarcoma of adults: meta-analysis of

individual data. Sarcoma Meta-analysis

Collaboration.

Tierney JF. Lancet

350, 1647-1654, 1997

16

Results of single-agents and combination

chemotherapy for advanced soft tissue sarcomas.

Implications for decision making in the clinic.

Demetri GD, et al.

Hematol. Oncol. Clin.

North Am.

9(4), 765-785, 1995

17

Prognostic factors for the outcome of

chemotherapy in advanced soft tissue sarcoma: An

analysis of 2,185 patients treated with

Anthracycline-containing first-line regimens-A

European Organization for Research and Treatment

of Cancer Soft Tissue and Bone Sarcoma Group

Study.

Van Glabbeke M,

et al.

J. Clin. Oncol.

17(1),150-157, 1999

18

Doxorubicin-based chemotherapy for the

palliative treatment of adult patients with

locally advanced or metastatic soft tissue

sarcoma (STS).Practice Guideline Report ＃11-1

Bramwell VHC, et

al.

http://hiru.mcmaster.

ca/ccopgi/guidelines/

sar, 2000

19

An assessment of the relative importance of the

components of CYVADIC in the treatment of

soft-tisssue sarcomas using regression

meta-analysis.

Crawford SM, et

al.

Med. Inform.

19(4), 311-321,1994

20 Perspectives on Anthracyclines plus Ifosfamide

in advanced soft tissue sarcomas. Casali P, et al.

Cancer Chemoth.

Pharmacol. 31(S-2),

S228-232, 1993

21 The role of chemotherapy in the management of

non-metastatic operable extremity osteosarcoma.Bramwell VHC.

Semin. Oncol.

24(5), 561-571, 1997

22 Osteosarcoma and other bone cancers. Himelstein BP. Curr. Opin. Oncol.

10, 326-333, 1998


23

NCI. Cancer Gov. Adult soft tissue

sarcoma(PDQ):Treatment health professional

version

―

http://cancer.gov/can

cerinfo/pdq/treatment

/adult-soft-tissu-sar

coma/healthprofession

al

24

NCI. Cancer Gov. Osteosarcoma/Malignant fibrous

histiocytoma of bone (PDQ):Treatment

health propessional version

―

http://cancer.gov/can

cerinfo/pdq/treatment

/osteosarcoma/healthp

rofessional

３

http://hiru.mcmaster.ca/ccopgi/guidelines/sarhttp://hiru.mcmaster.ca/ccopgi/guidelines/sarhttp://hiru.mcmaster.ca/ccopgi/guidelines/sarhttp://cancer.gov/cancerinfo/pdq/treatment/adult-soft-tissu-sarcoma/healthprofessionalhttp://cancer.gov/cancerinfo/pdq/treatment/adult-soft-tissu-sarcoma/healthprofessionalhttp://cancer.gov/cancerinfo/pdq/treatment/adult-soft-tissu-sarcoma/healthprofessionalhttp://cancer.gov/cancerinfo/pdq/treatment/adult-soft-tissu-sarcoma/healthprofessionalhttp://cancer.gov/cancerinfo/pdq/treatment/adult-soft-tissu-sarcoma/healthprofessionalhttp://cancer.gov/cancerinfo/pdq/treatment/osteosarcoma/healthprofessionalhttp://cancer.gov/cancerinfo/pdq/treatment/osteosarcoma/healthprofessionalhttp://cancer.gov/cancerinfo/pdq/treatment/osteosarcoma/healthprofessionalhttp://cancer.gov/cancerinfo/pdq/treatment/osteosarcoma/healthprofessional

小児

資料番号



1

Addition of Ifosfamide and Etoposide to standard

chemotherapy for Ewing’s sarcoma and primitive

neuroectodermal tumor of bone

Grier HE, et al.New Engl. J. Med.

348,694-701,2003

2

Multimodal therapy for the management of primary,

nonmetastatic Ewing’s sarcoma of bone: A long

-term follow-up of the first intergroup study

Nesbit ME Jr, et

al.

J. Clin. Oncol.

8(10),1664-1674,1990

3

Multimodal therapy for the management of

nonpelvic, localized Ewing’s sarcoma of bone:

Intergroup study IESS-Ⅱ

Burgert EO, et al.J. Clin. Oncol.

8(9),1514-1524,1990

4 The intergroup rhabdomyosarcoma study-Ⅰ Maurer HM, et al. Cancer

61,209-220,1988

5 The intergroup rhabdomyosarcoma study-Ⅱ Maurer HM, et al. Cancer

71,1904-1922,1993

6 The third intergroup rhabdomyosarcoma study Crist W, et al. J. Clin. Oncol.

13(3),610-630,1995

7

Treatment of intermediate risk rhabdomyosarcoma

and undifferentiated sarcoma with alternating

cycles of

Vincristine/Doxorubicin/Cyclophosphamide and

Etoposide/Ifosfamide

Arndt CAS, et al. Eur. J. Cancer

34(8),1224-1229,1998

8

Very intensive, short-term chemotherapy for

children and adolescents with metastatic

sarcomas

Felgenhauer J, et

al.

Med. Pediatr. Oncol.

34,29-38,2000

9

Treatment of high-risk neuroblastoma with

intensive chemotherapy, radiotherapy,

autologous bone marrow transplantation, and

13-cis-retinoic acid

Matthay KK, et al.

New Engl. J. Med.

341(16),1165-1173,19

99

10

Successful treatment of stageⅢ neuroblastoma

based on prospective biologic staging: A

children’s cancer group study

Matthay KK, et al.J. Clin. Oncol. 16(4),

1256-1264,1998

11

Prognostic significance of age, MYCN oncogene

amplification, tumor cell ploidy, and histology

in 110 infants with stage D(S) neuroblastoma: The

pediatric oncology group experience－A pediatric

oncology group study

Katzenstein HM, et

al.

J. Clin. Oncol.

16(6),2007-2017,1998

12

LMCE3 treatment strategy: Results in 99

consecutively diagnosed stage 4 neuroblastomas

in children older than 1 year at diagnosis

Frappaz D, et al. J. Clin. Oncol.

18(3), 468-476,2000

13 Extraocular retinoblastoma: A 13-year experienceAntoneli CBG, et

al.

Cancer

98,1292-1298,2003

14 A prospective study on the treatment of

retinoblastoma in 72 patients Zelter M, et al.

Cancer

68(8),1685-1690,1991

15 The role of chemotherapy in orbital involvement

of retinoblastoma Doz F, et al.

Cancer

74(2),722-732,1994

４

資料番号


16 Results of a stage-based protocol for the

treatment of retinoblastoma

Schvartzman E, et

al.

J. Clin. Oncol.

14(5),1532-1536,1996

17

Cisplatin, Doxorubicin, and delayed surgery for

childhood hepatoblastoma: A successful approach

- Results of the first prospective study of the

international society of pediatric oncology

Pritchard J, et al.

J. Clin. Oncol.

18(22),3819-3828,200

0

18

Randomized comparison of

Cisplatin/Vincristine/Fluorouracil and

Cisplatin/continuous infusion Doxorubicin for

treatment of pediatric hepatoblastoma: A report

from the children’s cancer group and the

pediatric oncology group

Ortega JA, et al.

J. Clin. Oncol.

18(14),2665-2675,200

0

19 The treatment of Wilms’ tumor: Results of the

second national Wilms’ tumor study D'Angio GJ, et al.

Cancer

47(9),2302-2311,1981

20 Treatment of Wilms’ tumor Results of the third

national Wilms’ tumor study D'Angio GJ, et al.

Cancer

64(2),349-360,1989

21

Results of the sixth international society of

pediatric oncology Wilms’ tumor trial and study:

A risk-adapted therapeutic approach in Wilms’

tumor

Tournade MF, et al.J. Clin. Oncol.

11(6),1014-1023,1993

22

Treatment of children with stage Ⅳ favorable

histology Wilms tumor: A report from the national

Wilms tumor study group

Green DM, et al.Med. Pediatr. Oncol.

26,147-152,1996

23

Comparison between single-dose and divided-dose

administration of Dactinomycin and Doxorubicin

for patients with Wilms’ tumor: A report from the

national Wilms’ tumor study group

Green DM, et al.J. Clin. Oncol.

16(1),237-245,1998

24

Optimal duration of preoperative therapy in

unilateral and nonmetastatic Wilms’ tumor in

children older than 6 months: Results of the ninth

international society of pediatric oncology

Wilms’ tumor trial and study

Tournade MF, et al.J. Clin. Oncol.

19(2),488-500,2001

②教科書

25 Ewing’s sarcoma family of tumors. Ginsberg JP, et al.

In Principle and

Practice of Pediatric

Oncology 4th ed (2002)

Pizzo PA, et al.eds.

Lippincott Williams

and Wilkins,PA,USA.

pp973-1016

26 Cancers of childhood. Helman LJ , et al.

In Cancer Principles

and Practice of

Oncology 6th ed.(2001)

DeVita VT, et al.eds.

Lippincott Williams

and Wilkins,PA, USA

pp2161-2214

５

資料番号


27 Rhabdomyosarcoma and the undifferentiated

sarcomas. Wexler LH, et al.

In Principle and




Lippincott Williams

and Wilkins,PA,USA.

pp939-971

28 Neuroblastoma. Brodeur GM, et al.

In Principle and




Lippincott Williams

and Wilkins,PA,USA.

pp895-937

29 Retinoblastoma. Hurwitz RL, et al.

In Principle and




Lippincott Williams

and Wilkins,PA,USA.

pp825-846

30 Tumors of the liver. Tomlinson GE, et

al.

In Principle and




Lippincott Williams

and Wilkins,PA,USA.

847-864

31※ Renal tumors. Grundy PE, et al.

In Principle and




Lippincott Williams

and Wilkins,PA,USA.


32 Treatment of Ewing sarcoma family of tumors:

Current status and outlook for the future

Rodriguez-Galindo

C, et al.


40,276-287,2003

33 Biology and therapy of pediatric

rhabdomyosarcoma Pappo AS,et al.

J. Clin. Oncol.

13(8),2123-2139,1995

34

Progress in the diagnosis and treatment of

rhabdomyosarcoma and related soft tissue

sarcomas

Ruymann FB, et al.Cancer Invest.

18(3),223-241,2000

35 Advances in the diagnosis and treatment of

neuroblastoma

Weinstein JL, et

al.

Oncologist

8,278-292,2003

36 Chemotherapy for retinoblastoma: An Expanding

area of clinical research Meeteren S, et al.


38,428-438,2002

６

資料番号


37 Where do we stand with hepatoblastoma? Schnater JM, et al.Cancer

98(4),668-678,2003

38 Management of Wilms’ tumor: current practice

and future goals

Kalapurakal JA, et

al.

Lancet Oncol.

5,37-46,2004


39 NCI. Cancer Gov. Ewing’s Family of Tumors（PDQ）：

Treatment Health Professional Version

http://www.cancer.go

v/cancerinfo/pdq/tre

atment/ewings/health

professional/

40 NCI. Cancer Gov. Neuroblastoma（PDQ）：Treatment

Health Professional Version

41 NCI. Cancer Gov. Childhood Rhabdomyosarcoma

（PDQ）：Treatment Health Professional Version



atment/childrhabdomy

osarcoma/healthprofe

ssional/

42 NCI. Cancer Gov.Retinoblastoma（PDQ）：Treatment

Health Professional Version



atment/retinoblastom

a/healthprofessional

/

43 NCI. Cancer Gov. Childhood Liver Cancer（PDQ）：

Treatment Health Professional Version



atment/childliver/he

althprofessional/

44

NCI. Cancer Gov.Wilms’Tumor and Other Childhood

Kidney Tumor（PDQ）：Treatment Health Professional

Version



atment/wilms/healthp

rofessional/

その他参考となる論文

45 Functional myocardial impairment in children

treated with Anthracyclines for cancer Yeung ST, et al.

Lancet

337，816-818，1991

46 Late cardiac effects of Doxorubicin therapy for

acute Lymphoblastic leukemia in childhood Lipshulz SE, et al.

New Engl. J. Med.

324(12)，808-815，1991

47 Cardiac Toxicity 4 to 20 Years After Completing

Anthracycline Therapy Steinherz LJ, et al.

JAMA.

266(12),1672-1677，

1991



atment/neuroblastoma

/healthprofessional/

※資料番号３１は未入手

７

http://www.cancer.gov/cancerinfo/pdq/treatment/ewings/healthprofessional/http://www.cancer.gov/cancerinfo/pdq/treatment/ewings/healthprofessional/http://www.cancer.gov/cancerinfo/pdq/treatment/ewings/healthprofessional/http://www.cancer.gov/cancerinfo/pdq/treatment/ewings/healthprofessional/http://www.cancer.gov/cancerinfo/pdq/treatment/childrhabdomyosarcoma/healthprofessional/http://www.cancer.gov/cancerinfo/pdq/treatment/childrhabdomyosarcoma/healthprofessional/http://www.cancer.gov/cancerinfo/pdq/treatment/childrhabdomyosarcoma/healthprofessional/http://www.cancer.gov/cancerinfo/pdq/treatment/childrhabdomyosarcoma/healthprofessional/http://www.cancer.gov/cancerinfo/pdq/treatment/childrhabdomyosarcoma/healthprofessional/http://www.cancer.gov/cancerinfo/pdq/treatment/retinoblastoma/healthprofessional/http://www.cancer.gov/cancerinfo/pdq/treatment/retinoblastoma/healthprofessional/http://www.cancer.gov/cancerinfo/pdq/treatment/retinoblastoma/healthprofessional/http://www.cancer.gov/cancerinfo/pdq/treatment/retinoblastoma/healthprofessional/http://www.cancer.gov/cancerinfo/pdq/treatment/retinoblastoma/healthprofessional/http://www.cancer.gov/cancerinfo/pdq/treatment/childliver/healthprofessional/http://www.cancer.gov/cancerinfo/pdq/treatment/childliver/healthprofessional/http://www.cancer.gov/cancerinfo/pdq/treatment/childliver/healthprofessional/http://www.cancer.gov/cancerinfo/pdq/treatment/childliver/healthprofessional/http://www.cancer.gov/cancerinfo/pdq/treatment/wilms/healthprofessional/http://www.cancer.gov/cancerinfo/pdq/treatment/wilms/healthprofessional/http://www.cancer.gov/cancerinfo/pdq/treatment/wilms/healthprofessional/http://www.cancer.gov/cancerinfo/pdq/treatment/wilms/healthprofessional/

悪性骨腫瘍に対するシスプラチンを用いた化学療法資料

番号表題著者

掲載雑誌

その他


1

A comparison of two short intensive adjuvant

chemotherapy regimens in operable osteosarcoma

of limbs in children and young adults: The first

study of the European Osteosarcoma Intergroup.

Bramwell VHC，et

al.

J Clin Oncol．

10,1579-1591, 1992

2

Randomised trial of two regimens of chemotherapy

in operable osteosarcoma: a study of the European

Osteosarcoma Intergroup.

Souhami RL，et

al.

Lancet

350，911-917， 1997

3

Neoadjuvant chemotherapy of osteosarcoma:

Results of a randomised cooperative trial

(COSS-82) with salvage chemotherapy based on

histological tumor response.

Winkler K, et al.J Clin Oncol．

6，329-337, 1988

4 Primary chemotherapy and delayed surgery for

nonmetastatic osteosarcoma ot the extremities. Bacci G, et al.

Cancer

72，3227-38，1993

5

Neoadjuvant chemotherapy for Osseous Malignant

Fibrous Histiocytoma of the Extremity: Results

in 18 Cases and Comparison with 112

Contemporary Osteosarcoma Patients Treated

with the Same Chemotherapy Regimen.

Bicci G, et al.

Journal of

Chemotherapy

9，293-9，1997

6

Neoadjuvant chemotherapy with Doxorubicin and

Cisplatin in malignant fibrous histiocytoma of

bone: A European osteosarcoma intergroup study.

Bramwell VHC, et

al.

J Clin Oncol.

17, 3260-9, 1999

②教科書

7 Oxford textbook of Oncology 5th Ed．

Oxford University Press － pp, 1917-1982

8 Treatment of Cancer 4th ed. Price P, et al. pp851-868, 2002


9

Influence of Doxorubicin dose intensity on

response and outcome for patients with

osteogenic sarcoma and Ewing’s sarcoma.

Smith MA, et al.J Natl Cancer Inst

83,1460-1470, 1991

10

Influence of methotrexate dose intensity on

outcome of patients with high grade osteogenic

osteosarcoma.

Delepine N, et

al.

Cancer

78,2127-2135,1996


11

NCI. Cancer Gov. Osteosarcoma/Malignant fibrous

histiocytoma of bone (PDQ): Treatment.

―

http://cancer.gov/

cancerinfo/pdq/tre

atment/osteosarcom

a/healthprofession

al

８

http://cancer.gov/cancerinfo/pdq/treatment/osteosarcoma/healthprofessionalhttp://cancer.gov/cancerinfo/pdq/treatment/osteosarcoma/healthprofessionalhttp://cancer.gov/cancerinfo/pdq/treatment/osteosarcoma/healthprofessionalhttp://cancer.gov/cancerinfo/pdq/treatment/osteosarcoma/healthprofessionalhttp://cancer.gov/cancerinfo/pdq/treatment/osteosarcoma/healthprofessional

子宮体癌ＡＰ療法

資料

番号表題著者

掲載雑誌

その他


1

A Randomized Comparison of Doxorubicin Alone Versus

Doxorubicin Plus Cyclophosphamide in the Management of

Advanced or Recurrent Endometrial Carcinoma: A

Gynecologic Oncology Group Study

Thigpen JT, et al.J Clin Oncol.

12(7), 1408-1414, 1994

2

PHASE III TRIAL OF DOXORUBICIN +/- CISPLATIN IN ADVANCED

OR RECURRENT ENDOMETRIAL CARCINOMA: A GYNECOLOGIC

ONCOLOGY GROUP (GOG) STUDY

Thigpen T, et al

Proc. Am. Soc. Clin.

Oncol.

12, 261, 1993

3

Doxorubicin versus doxorubicin and cisplatin in

endometrial carcinoma: definitive results of a

randomised study (55872) by the EORTC Gynaecological

Cancer Group

Aapro MS, et al. Ann. Oncol.

14(3), 441-448, 2003

4

Whole abdominal radiotherapy versus combination

doxorubicin-cisplatin chemotherapy in advanced

endometrial carcinoma: A randomized phase III trial of

the Gynecologic Oncology Group.

Randall ME, et al.


Oncol.

22, 2 (#3), 2003

②教科書

5※ CLINICAL ONCOLOGY Abeloff MD et al

Churchill

Livingstone

pp1585,1587-1588,

1999.

6 CORPUS: EPITHELIAL TUMORS

DISEASE SITES

Principles and Practice

of Gynecologic Oncology

3rd Edition (Edited by

Hoskins WJ, Perez CA,

Young RC)

pp939-940, 2000

7 Gynecologic Tumors

Carcinoma of the Endometrium Hoskins WJ et al.

CANCER Principles &

Practice of Oncology 3rd

Edition (Edited by

DeVita VT Jr, Hellman S,

Rosenberg SA)

pp1134-1144, 1989


8 Management of endometrial cancer Homesley HD et al.Am. J. Obstet. Gynecol.

174(2), 529-534, 1996

9 Cancer of the endometrium Bremond A, et al. Br. J. Cancer

2,31-36,2001

９

⑤総評に用いられた引用文献資料

番号表題著者

掲載誌名

その他

10

Phase II Trial of Adriamycin in the Treatment of Advanced

or Recurrent Endometrial Carcinoma: A Gynecologic

Oncology Group Study

Thigpen JT, et al.Cancer Treat Rep.

63(1),21-27, 1979

11

Phase II Trial of Cisplatin as First-Line Chemotherapy

in Patients with Advanced or Recurrent Endometrial

Carcinoma: A Gynecologic Oncology Group Study

Thigpen JT, et al Gynecol. Oncol.

33,68-70,1989

12 Treatment of recurrent endometrial adenocarcinoma with

a combination of doxorubicin and cisplatin Trope C, et al

Am. J. Obstet. Gynecol.

1984;

149(4),379-381,1984

13

Treatment of Advanced Endometrial Carcinoma With

Doxorubicin and Cisplatin: Effects on Both Untreated and

Previously Treated Patients

Pasmantier MW, et al Cancer Treat. Rep.

69(5), 539-542,1985

14 Comparative evaluation of cisplatin and carboplatin

sesitivity in endometrial adenocarcinoma cell lines Rantanen V, et al.

Br. J. Cancer

69(3),482-486,1994

15

FFICACY OF ANTICANCER AGENTS IN VITRO AND IN VIVO USING

CULTURED HUMAN ENDOMETRIAL CARCINOMA CELLS

--STUDY OF THERAPEUTIC INDEX--

Yasui Y Acta Obst. Gynaec. Jpn

39(2),303-306,1987

16

Randomized trial of doxorubicin (DOX) plus cisplatin

(CIS) versus DOX plus CIS plus paclitaxel (TAX) in

patients with advanced or recurrent endometrial

carcinoma: a Gynecologic Oncology Group (GOG) study

Fleming GF, et al

University of

Chicago Medical

Center


Oncol.

21,202a,2002

17

婦人科腫瘍委員会報告

第 37 回治療年報

「1980 年から 1989 年までに治療した子宮頸癌、体癌の５年

治療成績について」

日産婦誌

55(7),765-769,2003

18

婦人科腫瘍委員会

第 35 回治療年報

「1978 年～1987 年に治療した子宮頸癌の５年治療成績並び

に子宮体癌の５年治療成績」

日産婦誌

50(5),278-308,1998

第 38 回子宮癌研究会

子宮体癌の補助化学療法の評価

－予後からみた放射線療法との比較において－

杉山徹、他

子宮体癌に対する術後補助療法の検討山崎正明、他

当科における子宮体癌の治療と予後山本嘉一郎、他

19

当院における子宮体癌術後療法の治療成績宇田川康博、他

産科と婦人科

66(9),1173-1200,1999

20

ICON2: randomised trial of single-agent carboplatin

against three-drug combination of CAP

(cyclophosphamide, doxorubicin, and cisplatin) in women

with ovarian cancer

Parmar MKB, et al. Lancet

352,1571-1576,1998

21

Paclitaxel plus carboplatin versus standard

chemotherapy with either single-agent carboplatin or

cyclophosphamide, doxorubicin, and cisplatin in women

with ovarian cancer: the ICON3 randomised trial

Parmar MKB, et alLancet

360,505-515,2002

22

Improved Outcomes From Adding Sequential Paclitaxel but

Not From Escalating Doxorubicin Dose in an Adjuvant

Chemotherapy Regimen for Patients With Node-Positive

Primary Breast Cancer

Henderson IC, et al.

J. Clin. Oncol.

21(6),976-983,2003

※資料番号５は未入手

１０

骨髄腫ＶＡＤ療法

資料

番号表題等著者

掲載雑誌

その他


1 Effective treatment of advanced multiple myeloma

refractory to alkylating agents Barlogie B., et al.

New Engl. J. Med.

310:1353-1356 ,1984

2 VAD-based regimens as primary treatment for

multiple myeloma. Alexanian R., et al.

Am. J. Hematol.

33:86-89,1990

3 VAD chemotherapy as remission induction for

multiple myeloma Anderson H., et al.

Brit. J. Cancer

71:326-330,1995

4

Vincristine, doxorubicin and dexametasone (VAD)

administered as rapid intravenous infusion for

first-line treatment in untreated multiple

myeloma

Segeren C. M., et al. Brit. J. Haematol.

105:127-130,1999

5

Prospective randomized comparison of

vincristine, doxorubicin and dexamethasone(VAD)

administered as intravenous bolus injection and

VAD with liposomal doxorubicin as first-line

treatment in multiple myeloma

Dimopoulos M. A., et

al.

Ann. Oncol.

14:1039-1044 ,2003

6

Phase III study comparing vincristine,

doxorubicin (Adriamycin), and dexamethasone

(VAD) chemotherapy with VAD plus recombinant

interferon alfa-2 in refractory or relapsed

multiple myeloma. An Eastern Cooperative

Oncology Group study

Gertz M. A., et al. Am. J. Clin. Oncol.

18:475-480,1995

7

Induction therapy with vincristine, adriamycin,

dexamethasone (VAD) and intermediate-dose

melphalan (IDM) followed by autologous or

allogeneic stem cell transplantation in newly

diagnosed multiple myeloma

Lokhorst H. M., et

al.

Bone Marrow Transpl.

23:317-322,1999

8

Risk factors for the development of bacterial

infections in multiple myeloma treated with two

different vincristine-adriamycin-dexamethasone

schedules

Cesana C., et al. Haematologica.

88:1022-1028 ,2003

9

VAD or VMBCP in multiple myeloma refractory to or

relapsing after cyclophosphamide-prednisone

therapy (protocol MY 85)

Minew P., et al. Brit. J. Haematol.

103:512-517,1998

10 Cancer. Principle and practice of Oncology DeVita V.T., et al.

Lippincott Williams

& Wilkins,

Philadelphia,

5thed:pp. 2344-2387

②教科書

11 Wintrobe’s Clinical Hemtaology Wintrobe M. M.

Lippincott Williams

& Wilkins,

Philadelphia,

10thed:pp. 2659,1999

１１

資料

番号表題等著者

掲載雑誌

その他


該当なし


12 JCOG-LSG リンパ腫・骨髄腫臨床研究マニュアル第 1 版:頁 96

１２

アドリアシン注引用文献一覧表...Patel SR, et al. Am. J. Clin. Oncol. 21(3),317-321,...

Documents

Transcript of アドリアシン注引用文献一覧表...Patel SR, et al. Am. J. Clin. Oncol. 21(3),317-321,...

アドリアシン注 引用文献一覧表...Patel SR, et al. Am. J. Clin. Oncol. 21(3),317-321,...

Documents

Transcript of アドリアシン注 引用文献一覧表...Patel SR, et al. Am. J. Clin. Oncol. 21(3),317-321,...

アドリアシン注引用文献一覧表...Patel SR, et al. Am. J. Clin. Oncol. 21(3),317-321,...

Transcript of アドリアシン注引用文献一覧表...Patel SR, et al. Am. J. Clin. Oncol. 21(3),317-321,...